Proactive Investors - Run By Investors For Investors

Zelda Therapeutics secures patent to detect breast cancer

Building an intellectual property portfolio is part of Zelda's vertically integrated strategy.
folder titled patents
The patent provides protection until 2038

Zelda Therapeutics Ltd (ASX:ZLD) has been granted a new patent in Australia covering a novel method to predict patient disease-free survival.

The patent details a method for detecting levels of expression of a novel receptor complex containing HER2 and CB2 (types of protein).

HER2 is a well-recognised marker of aggressive breast cancer while CB2 is a key receptor in the endocannabinoid system.

Together they form a novel receptor complex that represents a prognostic marker for HER2 positive breast cancer.

READ: Zelda Therapeutics leveraged to study results that progress cannabis-based cancer therapies

Zelda’s managing director Dr Richard Hopkins said: “We’re delighted with the allowance of this patent, which supports Zelda’s strategy of building a world-class intellectual property portfolio and the development of cannabis-based products.

“Further news is expected as this patent family progresses through the international examination phase.

“I’d also like to acknowledge the work of Professor Cristina Sanchez and her team who generated the data that supported this patent.

“This work was recently published in the prestigious peer-reviewed Proceedings of the National Academy of Sciences.

“This outcome highlights the benefit of Zelda’s approach of partnering with world-leading cannabis researchers.

“Importantly, Professor Sanchez’s discovery of a novel prognostic biomarker, will complement our ongoing efforts develop to cannabis-based medicines to treat breast cancer.”

A vertically integrated medical cannabis strategy

The company’s focus remains on the development of novel cannabinoid-based therapies for a range of diseases.

Zelda is undertaking a human clinical trial program focused on insomnia, autism and opioid reduction with activities in Australia and the US.

Pre-clinical research activities include programs examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full ZLD profile View Profile

Zelda Therapeutics Ltd Timeline

Related Articles

cannabis on dollar bills
June 08 2019
Australis invests in the highly fragmented, rapidly evolving US cannabis space, with a focus on building companies through early-stage, diversified and opportunistic investments
muffins and cannabis
November 29 2018
Dehydratech is essentially a delivery system that allows drugs and vitamins to get into the bloodstream quicker, while making them taste and smell better at the same time
Cannabis leaf
November 19 2018
With the legalisation of recreational cannabis in Canada in October, and the US expected to follow suit, the company has its sights set on building up the very best in the industry
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use